Effect of argon knife in hepatic resection for hepatocellular carcinoma on postoperative recurrence and survival rate
LI De-fu, XIA Yong-hong, MA Ying
2020, 25(8):
819-821.
Asbtract
(
263 )
PDF (739KB)
(
383
)
References |
Related Articles |
Metrics
Objective To study the effect of argon knife dealing with liver cross section in hepatic resection for hepatocellular carcinoma on postoperative recurrence and survival rate. Methods A total of 144 patients with hepatocellular carcinoma admitted to our hospital from January 2014 to August 2016 received non-radical palliative resection and hepatic portal occlusion. The patients were randomly divided into 2 groups, 72 in each. The liver cross section was treated with traditional electric knife in the control group and argon knife in the observation group. The intraoperative and postoperative conditions (the residual hepatic cross section area, operation time, intraoperative blood loss, intraoperative blood transfusion volume, hepatic portal occlusion time, the total postoperative drainage volume, drainage days, and the postoperative hospital stay time) of the 2 groups were analyzed. The 6-month, 1-year, 2-year, 3-year survival rate, and 6-month, 9-month, 1-year, 2-year recurrence rate after operation were compared between the 2 groups. Results The intraoperative blood loss and transfusion volume in the observation group were significantly less than those in the control group (P<0.05). The postoperative 6-month, 1-year, 2-year and 3-year survival rates in the observation group were 91.67%, 62.50%, 27.78% and 13.89%, respectively, which were significantly higher than those in the control group (79.17%, 45.83%, 12.50% and 8.33%, respectively, P<0.05). The 6-month, 9-month, 1-year and 2-year recurrence rates after operation in the observation group were 31.94%, 63.89%, 77.78% and 86.11%, which were significantly lower than those in the control group (58.33%, 79.17%, 90.28% and 95.83%, respectively, P<0.05). Conclusion In the resection for hepatocellular carcinoma, argon knife can reduce the intraoperative blood loss and blood transfusion, lower the tumor recurrence, and improve the survival rate of patients.